THE EFFICACY AND SAFETY OF FOSTER IN PATIENTS WITH BRONCHIAL ASTHMA IN ROUTINE CLINICAL PRACTICEon behalf of the Research Group «ESTAFETA» to assess the efficacy and safety of the drug «Foster» in patients with asthma in routine clinical practice



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Evaluation of the efficacy and safety of the drug Foster (fixed combination of beclomethasone di-propionate 100 mcg and formoterol 6 micrograms per single dose) in metered-dose aerosol inhaler technology Modulite® in patients with bronchial asthma (BA).
Methods. Prospective non comparative multicenter open observational study. Study group consisted of 120 practicing physicians from the 92 hospitals in 21 cities of Russia. Analyzed 557 case report forms of patients with moderate persistent asthma treated with Foster during 12 weeks who needed to correct the basic therapy (according to asthma control criteria GINA 2006).
Results. The effectiveness of treatment with Foster was observed in 555 (99,6%) of 557 patients, who showed improvement in lung function, decreased severity of symptoms, reducing the need for symptomatic therapy compared with baseline and improved asthma control in general.
Conclusions. In most cases, control over moderate and severe persistent asthma can be improved by the combined therapy of inhaled steroids (ICS) and в2-agonist long-acting (LABA). In this case, Foster is a drug of choice with a fixed combination of ICS and LABA. Extra-fine form of the drug (thanks to innovative technology Modulite®) is evenly distributed in central and peripheral airways, providing good therapeutic effect of using of low doses of ICS and reducing the likelihood of side effects.

About the authors

N I Iljina

Institute of Immunology

Institute of Immunology

K S Pavlova

Institute of Immunology

Email: ksenimedical@gmail.com
Institute of Immunology

References

  1. Bai T.R., Knight D.A. Structural changes in the airways in asthma: observations and consequences. Clin. Sci. (Lond). 2005, v. 108, p. 463-477.
  2. Глобальная стратегия лечения и профилактики бронхиальной астмы (GINA. The Global Burden of Asthma), пересмотр 2006 г., пер. с англ. М., «Атмосфера». 2007.
  3. Bateman E.D., Bantje T.A., Joao Gomes M. et al. Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma. Am. J. Respir. Med. 2003, v. 2, p. 275-281.
  4. Lalloo U.G., Malolepszy J., Kozma D. et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest. 2003, v. 123, p. 1480-1487.
  5. Pauwels R.A., Lofdahl C.G., Postma D.S. et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N. Engl. J. Med. 1997, v. 337, р. 1405-1411.
  6. Ringdal N., Chuchalin A., Chovan L. et al. Evaluation of different inhaled combination therapies (EDICT): a randomized, double-blind comparison of Seretide (50/250 microg bd)Discus versus formoterol (12 microg bd) and budesonide (800 microg bd) given concurrently (both via Turbuhaler) in patients with moderate-to-serve asthma. Respir. Med. 2002, v. 96, p. 851-861.
  7. Tal A., Simon G., Vermeulen J.H. et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr. Pulmonol. 2002, v. 34, p. 342-350.
  8. Aubier M., Pieters W.r., Schlosser N.J., Steinmetz K.O. Salmeterol/fluticasone propionate (50/500 microg)in combination in a Diskus inhaler (Serertide) is effective and safe in the treatment of steroid-dependent asthma. Respir. Med. 1999, v. 93, p. 876-884.
  9. Chapman K.R., Ringdal N., Backer V. et al. Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhaler. Can. Respir. J. 1999, v. 6, p. 45-51.
  10. Rosenhall L., Elvstrand A., Tilling B. et al. One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma. Respir. Med. 2003, v. 97, p. 702-708.
  11. Hamid Q., Song Y, Kotsimbos T.C. et al. Inflamation of small airways in asthma. J. Allergy Clin. Immunol. 1997, v. 100, p. 44-51.
  12. Sutherland E.R., Martin R.J. Distal lung inflamation in asthma. Ann. Allergy Asthma Immunol. 2002, v. 89, p. 119-124.
  13. Bousquet J. Introduction. Modulite: simplifying the changeover. Respir. Mad. 2002, v. 96, Suppl. D, S1-S2.
  14. Lewis D., Brambilla G., Church T. BDP and formoterol association within a combination HFA solution MDI. Respir. Drug. Delivery. 2006, v. 3, p. 939-942.
  15. Rigamonti E., Kottakis I., Pelc M. et al. Comparison of a new extrafine beclometasone dipropionat HFA 134a-formulated pMDI with a standard BDP CFC pMDI in adults with moderate persistent asthma. Eur. Respir. J. 2006, v. 28 (Suppl 50), p. 1236 (Abstract).
  16. Papi A., Paggiaro P.L., Nicolini G. et al. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur. Respir. J. 2007, v. 29, p. 682-689.
  17. Papi A., Paggiaro P., Nicolini G. et al. Beclomethasone/ formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy, 2007, v. 62 (10), p. 1182-1188.
  18. Scichilone N., Battaglia S., Sorino C. et al. Effects of extra-fine inhaled beclomethasone/formoterol on both large and small airways in asthma. Allergy. 2010, v. 65 (7), p. 897-902.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2009



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies